Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/14507
Title: Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics
Authors: Chittasupho C.
Siahaan T.J.
Vines C.M.
Berkland C.
Keywords: abatacept
adalimumab
autoantibody
B7 antigen
belatacept
CD28 antigen
cholinergic receptor
corticosteroid derivative
cytokine
cytotoxic agent
cytotoxic T lymphocyte antigen 4
dacetuzumab
efalizumab
etanercept
galiximab
immunoglobulin
infliximab
intercellular adhesion molecule 1
intercellular adhesion molecule 1 antibody
ipilimumab
lymphocyte function associated antigen 1
major histocompatibility antigen class 2
membrane protein
methotrexate
natalizumab
programmed death 1 receptor
rituximab
thyrotropin receptor
ticilimumab
unindexed drug
antigen presenting cell
autoimmune disease
autoimmunity
B cell lymphoma
brain infection
brain ischemia
cell adhesion
cellular immunity
chronic lymphatic leukemia
Crohn disease
cytokine production
drug protein binding
drug receptor binding
drug targeting
drug withdrawal
human
immunological synapse
immunoregulation
immunostimulation
lymphocyte proliferation
melanoma
multiple myeloma
multiple sclerosis
nonhodgkin lymphoma
nonhuman
phase 1 clinical trial (topic)
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
priority journal
progressive multifocal leukoencephalopathy
psoriasis
review
rheumatoid arthritis
signal transduction
T lymphocyte activation
Animals
Autoimmune Diseases
Cell Adhesion
Drug Delivery Systems
Humans
Immune Tolerance
Immunological Synapses
Inflammation
Proteins
Signal Transduction
Issue Date: 2011
Abstract: Proteins participating in immunological signaling have emerged as important targets for controlling the immune response. A multitude of receptor-ligand pairs that regulate signaling pathways of the immune response have been identified. In the complex milieu of immune signaling, therapeutic agents targeting mediators of cellular signaling often either activate an inflammatory immune response or induce tolerance. This review is primarily focused on therapeutics that inhibit the inflammatory immune response by targeting membrane-bound proteins regulating costimulation or mediating immune-cell adhesion. Many of these signals participate in larger, organized structures such as the immunological synapse. Receptor clustering and arrangement into organized structures is also reviewed and emerging trends implicating a potential role for multivalent therapeutics is posited. © 2011 Future Science Ltd.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79961177838&doi=10.4155%2ftde.11.60&partnerID=40&md5=34201a5607326ab185a08e4094899c9d
http://ir.swu.ac.th/jspui/handle/123456789/14507
ISSN: 20415990
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.